Similarly, Liu et al. [19] provided evidence that compared with wild-type homozygote carriers, significant increased risk effects were associated with XRCC1 Arg399Gln variants (adjusted OR, 1.43; 95% CI, 1.05–1.92), which were more pronounced in patients with high-grade gliomas (adjusted OR, 1.46; 95% CI, 1.01–2.08). The gene discussed is XRCC1; the disease is glioma.